ClinicalTrials.Veeva

Menu
Charité Universitätsmedizin Berlin | Institute of Allergology (IFA) - Campus Benjamin Franklin logo

Charité Universitätsmedizin Berlin | Institute of Allergology (IFA) - Campus Benjamin Franklin

Research site

Site insights

Top conditions

Top treatments

CDX-0159
STAR-0215
BLU-263
CGT9486
LOU064
PHA-022121
EP262
THB001
Briquilimab
Remibrutinib

Parent organization

This site is a part of Charité Universitätsmedizin Berlin

Data sourced from clinicaltrials.gov

Contact this site

Team Study-Start-Up & Coordination

Verified by this site

Active trials

14 of 15 total trials

(HARBOR) Study to Evaluate Efficacy and Safety of BLU-263 Versus Placebo in Patients With Indolent Systemic Mastocytosis

This is a randomized, double-blind, placebo-controlled, Phase 2/3 study comparing the efficacy and safety of elenestinib (BLU-263) + best supportive...

Enrolling
Monoclonal Mast Cell Activation Syndrome
Smoldering Systemic Mastocytosis
Drug: Placebo
Drug: Elenestinib

This is a multi-part, randomized, double-blind, placebo-controlled Phase 2 clinical study comparing the safety and efficacy of bezuclastinib (CGT9486...

Enrolling
Mastocytosis
Mastocytosis, Systemic
Drug: Bezuclastinib Tablets (Formulation A)
Drug: Placebo Tablets

The purpose of this trial is:1. to assess the efficacy, pharmacokinetics, and safety of remibrutinib vs. placebo in adolescents from 12 to \< 18 year...

Enrolling
Chronic Spontaneous Urticaria
Drug: placebo
Drug: LOU064 (blinded)

The goal of this trial is to enable the collection of information about long-term safety and clinical activity of STAR-0215 in participants with here...

Invitation-only
Hereditary Angioedema
Drug: STAR-0215

The purpose of this study is to assess the clinical effect, the pharmacodynamics, the safety, and the pharmacokinetics of barzolvolimab (CDX-0159) in...

Active, not recruiting
Chronic Spontaneous Urticaria
Biological: barzolvolimab
Drug: Matching Placebo

The purpose of this study is to assess the clinical effect, the pharmacodynamics, the safety, and the pharmacokinetics of barzolvolimab (CDX-0159) in...

Active, not recruiting
Chronic Inducible Urticaria
Drug: Matching Placebo
Biological: barzolvolimab

The goal of this clinical trial is to test the drug STAR-0215 in participants with hereditary angioedema (HAE). One group of participants will get 1...

Active, not recruiting
Hereditary Angioedema
Drug: STAR-0215

The purpose of this extension study is to collect long-term efficacy, safety and tolerability data on remibrutinib in a selected group of participant...

Enrolling
Chronic Spontaneous Urticaria
Drug: LOU064 (blinded)
Drug: LOU064 (open label)

The purpose of this study is to investigate the safety, PK / PD, and efficacy of SC CSL312 for prophylactic treatment of pediatric subjects with HAE.

Enrolling
Hereditary Angioedema (HAE)
Biological: CSL312

This trial will be performed as a three-part dose escalating clinical trial where Parts 1 is open label and Parts 2 and 3 are randomized, double-blin...

Enrolling
Chronic Spontaneous Urticaria
Drug: Briquilimab
Other: Placebo

This study evaluates the safety and efficacy of long-term on-demand treatment with orally administered deucrictibant for acute hereditary angioedema...

Enrolling
Hereditary Angioedema - Type 2
Hereditary Angioedema Types I and II
Drug: deucrictibant low dose
Drug: deucrictibant selected dose

This phase 1b trial will evaluate the effects of EP262 in subjects with Chronic Inducible Urticaria (CIndU), including symptomatic dermographism and...

Enrolling
Chronic Inducible Urticaria
Drug: Oral EP262

Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effects of EP262 in Subjects with Chronic Spontaneous Urtica...

Enrolling
Chronic Spontaneous Urticaria
Drug: Placebo
Drug: Oral EP262

This is a multicenter pharmacokinetic (PK) subtrial to investigate the PK profile of KVD900 in adolescent patients 12 to 17 years of age with Heredit...

Enrolling
Hereditary Angioedema
Drug: KVD900 600 mg

Trial sponsors

A
Celldex Therapeutics logo
E
Novartis logo
B
CSL Behring logo
C
J
KalVista Pharmaceuticals logo
P

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems